Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA2183||ECOG-ACRIN||A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY008||NRG||A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0525||RTOG||Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-40601||CALGB||Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GI004||NRG||Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E4512||ECOG||A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU003||NRG||A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z1041||ACSOG||A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients with HER-2 Positive Operable Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY019||NRG||A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-C-08||NSABP||A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU); Leucovorin; and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon||Adult CIRB - Late Phase Emphasis||Completed|